Structure and properties of lymphocytes’ surfaces in patients with chronic lymphoblastic leucosis

In the investigation that was performed, the authors studied the structure and properties of lymphocytes’ surfaces in patients with chronic lymphoblastic leukemia with application of atomic force microscopy technology. It was stated that development of chronic lymphoblastic leukemia is characterized with circulation of immature forms of lymphocytic series in peripheral bloodstream, for which increase of surface potential by 456% (p<0.05) as compared with control group, is typica

Evaluation of the elastic properties and topography of leukocytes’ surface in patients with type 2 diabetes mellitus using atomic force microscope

The aim of study was to examine some morphometrical parameters (height, diameter) of the leukocytes (white blood cells - WBCs), their specific surface morphology (globular prominences and depression in WBCs) as well as their local elastic properties (Young’s modulus) in healthy persons and in patients with type 2 diabetes mellitus (T2DM) by means of the atomic force microscopy (AFM). Morphological and morphometrical parameters of human leukocytes were evaluated by AFM in tapped mod

Gamma radiation attenuation characteristics of composites based on polyimide track membranes filled with nanodispersed Pb

The paper presents data on the effect of γ-radiation on polymer composites based on polyimide track membranes filled with nanodispersed lead. The radiation-protective properties of the composites were studied by theoretical and experimental method

Production of Bst polymerase for diagnosis of different infections using loop-mediated isothermal amplification

Introduction. The large fragment of DNA polymerase I from Geobacillus stearothermophilus GIM1.543 (Bst DNA polymerase) possesses 5'-3' DNA polymerase activity, 5'-3' displacement activity and high processivity. These properties make it possible to use Bst DNA polymerase in loop-mediated isothermal amplification (LAMP), which provides highly specific amplification of the target sequence and is used for rapid detection of agents causing human infectious diseases. The purpose of the study was to produce a recombinant Bst polymerase enzyme in the bacterial expression system and to assess its properties for LAMP-based diagnostics of infectious diseases. Materials and methods. Expression constructs carrying the Bst polymerase gene were obtained using genetic engineering techniques. Different Escherichia coli strains were used for protein expression. Metal-chelate and gel filtration chromatography techniques were used for protein purification. Catalytic characteristics of the enzyme were assessed in loop-mediated isothermal amplification reactions using AmpliSens SARS-CoV-2-IT, AmpliSens IAV-IT and AmpliSens IBV-IT diagnostic systems designed for high-quality detection of SARS-CoV-2, influenza A virus (IAV) and influenza B virus (IBV) RNA, respectively. Results. The offered protocol for production, extraction and purification of recombinant Bst polymerase makes it possible to produce the enzyme in the bacterial expression system using E. coli cells in a soluble form and reaching the yield up to 20% of the total cell mass. In LAMP reactions, the obtained enzyme demonstrates activity comparable with that of the commercial enzyme Bst 2.0 (NEB). Conclusion. Considering the fast purification and production of the enzyme, the obtained recombinant Bst polymerase can be used in LAMP-based diagnostic kits

ТРОМБОЛИТИЧЕСКАЯ И АНТИКОАГУЛЯНТНАЯ ТЕРАПИЯ ПРИ ТРОМБОЭМБОЛИИ ЛЕГОЧНОЙ АРТЕРИИ С ВЫСОКИМ И ПРОМЕЖУТОЧНЫМ РИСКОМ РАННЕЙ СМЕРТИ. ЧАСТЬ 1. ЛЕТАЛЬНОСТЬ И ОСЛОЖНЕНИЯ

Background The advantages of thrombolytic therapy over anticoagulant therapy in the treatment of acute pulmonary embolism are uncertain. Aim of study To compare primary outcomes and incidence of complications in patients with PE of high and intermediate risk in the course of TLT or ACT and to assess efficacy and safety of TLT and ACT. Study Design Prospective non-randomized study. Intervention was administration of a thrombolytic, the control group consisted of patients who had an anticoagulant introduced. Characteristics of a sample 503 patients with a high and intermediate risk of early death at the age of 16 to 93 years (mean age 61±16, Ме 63 (51; 74) admitted to the resuscitation department in 2011–2016. Thrombolytics were administered to 222 patients, heparin — 281. Results The mortality rate was 10.8% (24/222) when treated with thrombolytic vs. 17.8% (50/281) with anticoagulant treatment; odds ratio was 0.56, 95% confidence interval 0.32; 0.97; p=0.031; P=0.60. The mortality rate in the subgroup with unstable hemodynamics was 30.2% (19/63) with thrombolytics vs. 47.1% (32/68) with anticoagulant treatment; OR 0.49 (0.22; 1.06); p=0.051; P=0.51. The mortality rate in the subgroup of intermediate risk was 3.2% (5/158) vs. 8.4% (18/214); OR 0.36 (0.11; 1.05); p=0.049; P=0.54. The use of thrombolytic was associated with a decrease in mortality: in the age group&lt; 75 (mortality rate 5.5% (10/181) vs. 16.2% (33/204), OR 0.30 (0.14; 0.67); p=0.001, P=0.92); in the subgroup with acute cardiac arrhythmias (mortality rate 4.5% (1/122) vs. 44.0% (11/25); OR 0.061 (0.003; 0.557); p=0.002; P=0.91); in the subgroup with no hospital recurrence of embolism (mortality rate 1.6% (3/188) vs. 12.9% (32/248); OR 0.14 (0.03; 0.46), p&lt; 0.001; P=1.0). With thrombolysis, infarction pneumonia developed less often: in 19.8% (44/222) vs. 28.8% (81/281); OR 0.61 (0.39; 0.95); p=0.022; P=0.64. There were no differences in the incidence of hemorrhagic complications in the treatment of thrombolytics in comparison with anticoagulant therapy: 7.7% (17/222) vs. 10.3% (29/281); OR 0.72 (0.37; 1.40); p=0.35; P=0.17. Severe hemorrhages (including intracranial): 2.7% (6/22) vs. 3.2% (9/281); OR 0.84 (0.26; 2.62); p=0.80; P=0.06. Minor hemorrhages: 5.0% (11/ 222) vs. 7.1% (20/281); OR 0.72 (0.31; 1.63); p=0.36; P=0.16. Intracranial hemorrhages: 0.90% (2/222) vs. 0.71% (2/281); OR 1.27 (0.13; 12.67); p=0.81; P=0.13). There was no difference in the re-occurrence of embolisms: 15.3% (34/222) and 11.7% (33/281); OR 1.36 (0.79; 2.35); p=0.29; P=0.22. Conclusion Thrombolytic therapy appeared to be more effective for survival compared to anticoagulant therapy with no differences in the incidence of complications.АКТУАЛЬНОСТЬ Преимущества тромболитической терапии перед антикоагулянтной в лечении острой легочной эмболии неопределенны.Цель исследования Провести сравнительный анализ первичных исходов — летальности и частоты развития осложнений у пациентов с тромбоэмболией легочной артерии высокого и промежуточного риска при проведении тромболитической (ТЛТ) или антикоагулянтной терапии (АКТ). Оценить эффективность и безопасность ТЛТ и АКТ.Дизайн исследования Проспективное нерандомизированное исследование. Вмешательством являлось введение тромболитика, группой контроля — пациенты, которым вводился антикоагулянт.Характеристика выборки 503 пациентов высокого и промежуточного риска ранней смерти в возрасте от 16 до 93 лет (средний возраст 61±16, Ме 63 (51; 74) лет), поступивших в реанимационное отделение в 2011–2016 гг; 290 женщин, 213мужчин; тромболитик вводился 222 больным, гепарин — 281.Результаты Летальность при лечении тромболитиком 10,8% (24/222) против 17,8% (50/281) при лечении антикоагулянтом; отношение шансов 0,56, 95% доверительный интервал 0,32; 0,97; р=0,031; мощность (P) 0,60. Летальность в подгруппе с нестабильной гемодинамикой при введении тромболитика 30,2% (19/63) против 47,1% (32/68) при введении антикоагулянта; отношение шансов (ОШ) 0,49 (0,22; 1,06); р=0,051; Р=0,51. Летальность в подгруппе промежуточного риска 3,1% (5/159) против 8,5% (18/213); ОШ 0,35 (0,11; 1,04); р=0,048; Р=0,58. Использование тромболитика было ассоциировано со снижением летальности: в возрастной подгруппе&lt; 75 лет (летальность 5,5% (10/181) против 16,2% (33/204); ОШ 0,30 (0,14; 0,67); р=0,001; Р=0,92); в подгруппе с острыми нарушениями сердечного ритма (летальность 4,5% (1/22) против 44,0% (11/25); ОШ 0,061 (0,003; 0,557), р=0,002; Р=0,91); в подгруппе с отсутствием госпитального рецидива эмболии (летальность 1,6% (3/188) против 12,9% (32/248); ОШ 0,14 (0,03; 0,46); р&lt;0,001; Р=1,0). При тромболизисе реже развивалась инфарктная пневмония: в 19,8% (44/222) против 28,8% (81/281); ОШ 0,61(0,39; 0,95); р=0,022; Р=0,64. Не было выявлено различий в частоте геморрагических осложнений при лечении тромболитиком по сравнению с антикоагулянтом: 7,7% (17/222) против 10,3% (29/281); ОШ 0,72 (0,37; 1,40); р=0,35; Р=0,17. Тяжелые кровотечения (включая интракраниальные): 2,7% (6/22) против 3,2% (9/281); ОШ 0,84 (0,26; 2,62); р=0,80; Р=0,06. Незначительные кровотечения: 5,0% (11/222) против 7,1% (20/281); ОШ 0,72 (0,31; 1,63); р=0,36; Р=0,16. Интракраниальные кро- вотечения: 0,90% (2/222) против 0,71% (2/281); ОШ 1,27 (0,13; 12,67); р=0,81; Р=0,13). Не раз- личалась и частота повторных эмболий: 15,3% (34/222) и 11,7% (33/281); ОШ 1,36 (0,79; 2,35); р=0,29; Р=0,22. Заключение Тромболитическая терапия по сравнению с антикоагулянтной была эффективней для выживания; при этом статистически значимых различий в частоте развития осложнений не было выявлено. Ключевые слова: легочная эмболия, тромболитическая терапия, антикоагулянтная терапия, промежуточный риск неблагоприятного исхода, летальность, интракраниальные кровотечения, нарушения сердечного ритма&gt;&lt; 0,001; Р=1,0). При тромболизисе реже развивалась инфарктная пневмония: в 19,8% (44/222) против 28,8% (81/281); ОШ 0,61(0,39; 0,95); р=0,022; Р=0,64. Не было выявлено различий в частоте геморрагических осложнений при лечении тромболитиком по сравнению с антикоагулянтом: 7,7% (17/222) против 10,3% (29/281); ОШ 0,72 (0,37; 1,40); р=0,35; Р=0,17. Тяжелые кровотечения (включая интракраниальные): 2,7% (6/22) против 3,2% (9/281); ОШ 0,84 (0,26; 2,62); р=0,80; Р=0,06. Незначительные кровотечения: 5,0% (11/222) против 7,1% (20/281); ОШ 0,72 (0,31; 1,63); р=0,36; Р=0,16. Интракраниальные кровотечения: 0,90% (2/222) против 0,71% (2/281); ОШ 1,27 (0,13; 12,67); р=0,81; Р=0,13). Не различалась и частота повторных эмболий: 15,3% (34/222) и 11,7% (33/281); ОШ 1,36 (0,79; 2,35); р=0,29; Р=0,22.Заключение Тромболитическая терапия по сравнению с антикоагулянтной была эффективней для выживания; при этом статистически значимых различий в частоте развития осложнений не было выявлено

Primary Outcome of Emotional Burnout Studies of Siberian Railway Locomotive Engineers

The article represents the primary outcome of studies of emotional burnout expression and development of Siberian railway locomotive engineers of various age groups and work experience. Most attention is drawn to the preservation problem of their health and stable working capacity that influence railroad-traffic safety. The information about absence of distinct connection between symptoms of emotional burnout and work experience became available. The materials of the studies allow verifying the existing in literature statement about the nature of emotional burnout and also bring out scientific discussion about influence of age and personal traits of specialists in various areas on emotional burnout expression. The results of the studies can be applied in comparative analysis of emotional burnout among representatives of related or other professions

Structure and properties of lymphocytes’ surfaces in patients with chronic lymphoblastic leucosis

In the investigation that was performed, the authors studied the structure and properties of lymphocytes’ surfaces in patients with chronic lymphoblastic leukemia with application of atomic force microscopy technology. It was stated that development of chronic lymphoblastic leukemia is characterized with circulation of immature forms of lymphocytic series in peripheral bloodstream, for which increase of surface potential by 456% (p<0.05) as compared with control group, is typica

Evaluation of the elastic properties and topography of leukocytes’ surface in patients with type 2 diabetes mellitus using atomic force microscope

The aim of study was to examine some morphometrical parameters (height, diameter) of the leukocytes (white blood cells - WBCs), their specific surface morphology (globular prominences and depression in WBCs) as well as their local elastic properties (Young’s modulus) in healthy persons and in patients with type 2 diabetes mellitus (T2DM) by means of the atomic force microscopy (AFM). Morphological and morphometrical parameters of human leukocytes were evaluated by AFM in tapped mod